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The structural and biochemical characterization of broadly neutralizing anti-
HIV-1 antibodies (bNAbs) has been essential in guiding the design of potential
vaccines to prevent infection by HIV-1. While these studies have revealed
critical mechanisms by which bNAbs recognize and/or accommodate N-glycans
on the trimeric envelope glycoprotein (Env), they have been limited to the
visualization of high-mannose glycan forms only, since heterogeneity introduced
from the presence of complex glycans makes it difficult to obtain high-resolution
structures. 3.5 and 3.9 A˚ resolution crystal structures of the HIV-1 Env trimer
with fully processed and native glycosylation were solved, revealing a glycan
shield of high-mannose and complex-type N-glycans that were used to define the
complete epitopes of two bNAbs. Here, the refinement of the N-glycans in the
crystal structures is discussed and comparisons are made with glycan densities in
glycosylated Env structures derived by single-particle cryo-electron microscopy.
1. Introduction
The trimeric HIV-1 envelope glycoprotein (Env), the only
target of neutralizing antibodies, is among the most heavily
glycosylated proteins ever characterized (Lasky et al., 1986). It
includes glycans constituting up to 50% of its mass attached
to 30  3 potential N-linked glycosylation sites (PNGSs) per
gp120–gp41 protomer. PNGSs can be easily identified in
protein sequences as a three-residue sequon: Asn-X-Ser/Thr.
During transit through the endoplasmic reticulum, high-
mannose forms of N-linked glycans are attached to the Asn;
the high-mannose glycans are usually modified to complex-
type N-glycans during subsequent trafficking though the Golgi
apparatus (Fig. 1). Because of steric constraints that limit the
activities of endoplasmic reticulum and Golgi carbohydrate-
processing enzymes, the HIV-1 Env glycoprotein includes
regions of under-processed N-glycans in oligomannose forms
(Man5–9GlcNAc2), especially in the intrinsic mannose patch
on gp120, which forms portions of the epitopes for many
characterized HIV-1 broadly neutralizing antibodies (bNAbs;
Doores, 2015). Although oligomannose glycans dominate
parts of HIV-1 Env such as the N332gp120 glycan-associated
region on gp120, processed complex-type N-glycans pre-
dominate at N-linked glycosylation sites on gp41 and gp41-
proximal regions of gp120 (Behrens et al., 2016) and are
thought to protect the host receptor (CD4) binding site
(CD4bs) and the V3 loop of gp120 (Binley et al., 2010).
Viral glycans are generally non-immunogenic because they
are assembled by host cell machinery; thus, the carbohydrates
decorating the surface of HIV Env constitute a ‘glycan shield’
that reduces access to underlying protein epitopes (Kwong et
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al., 1998). Structural studies of bNAbs bound to HIV Env
trimers revealed mechanisms by which bNAbs targeting
various epitopes penetrate the glycan shield to either accom-
modate or include N-glycans in their epitopes (Julien et al.,
2013; Pancera et al., 2014; Scharf et al., 2015; Garces et al., 2015;
Lee et al., 2015, 2016; Stewart-Jones et al., 2016). However,
because heterogeneous glycosylation generally prevents the
formation of well ordered crystals, all HIV Env crystal struc-
tures had been solved using glycoproteins produced in
exclusively high-mannose forms (Diskin et al., 2011, 2013;
Kwon et al., 2015; Garces et al., 2015; Julien et al., 2013; Kong et
al., 2015; Pancera et al., 2014; Scharf et al., 2014, 2015; Stewart-
Jones et al., 2016; Zhou et al., 2010, 2013, 2015; Kwong et al.,
1998). Therefore, little was known about the structure of the
native HIV-1 Env glycan shield that includes both complex-
type and oligomannose N-glycans, and the natively glycosyl-
ated epitopes of important HIV-1 bNAb classes, such as
Asn332gp120 glycan/V3 loop and CD4bs bNAbs, remained
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Figure 1
High-mannose N-glycans are added to Asn-X-Ser/Thr sequons in the endoplasmic reticulum (first two panels) and can be modified into complex-type
glycans in the Golgi apparatus (third and fourth panels). Inhibitors such as kifunensine or growth in mutant mammalian cell lines (GnTI expression)
limits N-linked glycan addition to high-mannose forms. Complex-type glycans are distinguished from high-mannose glycans by the addition of a core
fucose at the base and negatively charged sialic acids at the tips.
Figure 2
Side and top views of PDB entry 5t3x: 3.9 A˚ resolution crystal structure of natively glycosylated Env trimer (gp120, brown; gp41, pink) in complex with
bNAb Fabs IOMA (blue) and 10-1074 (green). PNGSs modeled as high-mannose (cyan) or complex glycans (magenta) are shown as spheres.
incompletely characterized. We recently described crystal
structures of a natively glycosylated Env trimer bound to two
HIV-1 bNAbs (10-1074 and IOMA), which recognize the
gp120 V3 loop and CD4bs, respectively (Gristick et al., 2016).
Analysis of the native glycan shield on HIV-1 Env allowed the
first full description of the interplay between heterogeneous
untrimmed high-mannose and complex-type N-glycans within
the CD4bs, V3-loop and other epitopes on Env, revealing
antibody-vulnerable glycan holes and roles of complex-type
N-glycans on Env that are relevant to vaccine design. Here, we
describe the crystallographic refinement of N-glycans in these
structures in more detail and compare them with lower reso-
lution cryo-EM structures of natively glycosylated HIV-1 Env.
2. Crystal structures of natively glycosylated Env
trimer–Fab complexes
Apart from two exceptions (Scharf et al., 2015; Stewart-Jones
et al., 2016), previous HIV Env trimer crystal structures used
proteins produced in cells that attached only high-mannose-
type N-glycans (Julien et al., 2013; Pancera et al., 2014; Scharf
et al., 2015; Garces et al., 2015; Stewart-Jones et al., 2016) that
were then further enzymatically trimmed to reduce the glycans
to singleN-acetylglucosamines (GlcNAcs) at accessible PNGSs.
Our crystals were obtained from a natively glycosylated Env
trimer (BG505 SOSIP.664; Sanders et al., 2013) that was
prepared from human embryonic kidney cells (HEK 293 6E
cells) that attached both complex-type and high-mannose
N-glycans. The Env trimer was complexed with Fabs from the
CD4bs bNAb IOMA and from 10-1074, a V3 loop/N332gp120
glycan-directed bNAb (Mouquet et al., 2012). We solved
independent IOMA–10-1074–BG505 complex structures at
resolutions of 3.5 A˚ (PDB entry 5t3z) and 3.9 A˚ (PDB entry
5t3x) using BG505 protein prepared from different size-
exclusion chromatography fractions (Gristick et al., 2016).
These structures revealed an Env trimer bound to three
10-1074 and three IOMA Fabs (Fig. 2). 19 N-glycans (one
GlcNAc up to complex-type tetra-antennary) were visible per
gp120–gp41 protomer, forming glycan architectures extending
30 A˚ from the trimer surface.
3. Glycan interpretation and refinement
The overall glycan geometry was validated using programs
including PDB CArbohydrate REsidue check (pdb-care; http://
www.glycosciences.de/tools/pdb-care/), CArbohydrate Rama-
chandran Plot (carp; http://www.glycosciences.de/tools/carp/)
and Privateer (Agirre et al., 2015; Agirre, 2017). Glycans were
built into the initial models for the 3.9 and 3.5 A˚ resolution
IOMA–10-1074–BG505 crystal structures using 2Fo Fc maps
calculated with model phases and using composite-annealed
OMIT maps calculated with phases from which the model was
omitted (Adams et al., 2010). Well characterized glycans
known to exist in a homogeneous population (e.g. N332gp120)
were modeled using structural information from published
BG505 trimer structures. Glycans at these positions were
examined for correct geometry and then merged into the
appropriate position in our models. Once imported, these
glycans were then manually fitted into our density in Coot
(Emsley et al., 2010).
For glycans lacking previous structural information, we
performed de novo modeling into the initial electron-density
maps using the carbohydrate-building module in Coot. Owing
to a lack of heavily glycosylated protein structures in the PDB,
the majority of glycosylation sites were modeled in this way.
Modeling was performed one glycosylation site at a time
followed by refinement in PHENIX (Adams et al., 2010) using
torsion restraints to prevent the glycans from puckering and
adopting an incorrect conformation. This was carried out until
glycans were modeled into all of the visible density within the
glycosylation sites.
Following multiple rounds of building and refinement, the
glycan geometry was examined using Privateer within the
CCP4 suite (Agirre et al., 2015). As demonstrated, even with
torsion restraints present during refinement in PHENIX, our
fully glycosylated initial model contained numerous glycans
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Figure 3
Cremer–Pople analysis of the initial model (left) and the final model (PDB entry 5t3x) after iterative building and refinement (right). Note that a larger
fraction of the glycans in the initial model were in high-energy conformations with significant puckering, which shifted to the more common lower energy
conformations following refinement.
with incorrect geometries and conformations (Fig. 3, left
panel). Analysis with Privateer generated a new cif file
containing updated restraints for each glycan type present in
our structure. This cif file proved to be better at maintaining
the correct glycan geometries and conformations when used in
place of the default PHENIX restraints during subsequent
refinements, which along with iterative manual modeling
corrected the glycan geometries as seen in the final deposited
model, PDB entry 5t3x (Fig. 3, right panel).
The initial unbiased maps, calculated using a model lacking
glycans, displayed clear density for 19 glycans. However, the
nature and extent of this density varied greatly between each
PNGS. PNGSs containing heterogenous populations of
glycans, such as N156gp120 and N276gp120, contained weaker
density present in the initial electron-density maps that
became more apparent after subsequent building and refine-
ment (Fig. 4, first and second rows). In contrast, PNGSs
containing homogenous populations of glycans, such as
N332gp120 and N386gp120, had clear density that remained
unchanged during refinement (Fig. 4, third and fourth rows).
Therefore, less defined maps at PNGSs can be indicative of
the presence of complex N-glycans since these are generally
heterogeneous.
Glycans could sometimes be assigned at individual PNGSs
as complex-type or high mannose by the presence of a core
fucose ring that is found in complex-type, but not in high-
mannose, N-glycans. The 3.9 A˚ resolution structure generally
showed more density for individual BG505 N-glycans than the
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Figure 4
Comparison of the initial 2Fo (left), final 2Fo (center) and OMIT (right) maps for the 3.9 and 3.5 A˚ resolution structures at PNGSs N156gp120 (first row),
N276gp120 (second row), N332gp120 (third row) and N386gp120 (fourth row). All maps are contoured at 0.8.
3.5 A˚ resolution structure, consistent with the presence of
larger, more branching complex N-glycan architectures in the
3.9 A˚ resolution structure. Glycans were assigned as complex-
type if there was density for a core fucose and/or based on
mass-spectrometry assignments (Behrens et al., 2016; Go et al.,
2011). A core fucose was sometimes visible in one structure
but not in the other. Glycans at some individual PNGSs were
therefore interpreted with different compositions in the two
structures; this type of heterogeneity is consistent with
multiple glycoforms at single PNGSs in preparations of the
BG505 SOSIP.664 protein (Behrens et al., 2016).
Although the composite-annealed OMIT maps displayed
additional density near PNGSs compared with the maps
calculated with model phases, some of the extra densities were
not interpretable. Therefore, glycan residues were not built
into these regions so as to avoid overfitting owing to a lack of
supporting information (for example mass spectrometry). In
contrast to the presence of these larger, branching glycans,
some glycans were only partially
ordered. Thus, a complex-type
glycan could appear to be a small
high-mannose glycan in our
electron-density maps if the core
fucose and residues beyond the
core pentasaccharide were dis-
ordered, since this portion of
an N-glycan is common to both
high-mannose and complex-type
N-glycans. In other cases, the
interpretation of our electron-
density maps was partially based
on supporting experimental data:
e.g. for the N301gp120 glycan a
core fucose was not ordered in
our maps, but the N301gp120
glycan was modeled as complex-
type in our structures based on
mass-spectrometric data (Go et
al., 2011). As expected given the
large degree of glycan hetero-
geneity in HIV-1 Env (Doores,
2015), the glycan density was
sometimes ambiguous. Consistent
with the notion that unin-
terpretable glycan density results
from sample heterogeneity rather
than from refinement problems,
we found unambiguous density at
positions that should be homo-
genous, e.g. at N332gp120, a
high-mannose-only site (Behrens
et al., 2016), whereas sites
predicted to be more hetero-
geneous, such as N156gp120
(Behrens et al., 2016; Go
et al., 2011), exhibited some
uninterpretable heterogeneous
electron density. Although the
relatively low resolution of
our crystal structures and
heterogeneous glycosylation
compounded inherent difficulties
in making unambiguous glycan
assignments, we built coordinates
into very extensive densities (e.g.
a complex glycan attached to
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Figure 5
Comparison of the density at selected PNGSs from the 6.2 and 8.9 A˚ resolution cryo-EM maps.
Asn276gp120), even if the exact structure of the glycan was
uncertain, to demonstrate the extent of glycosylation at each
PNGS. Additional confidence in electron-density interpreta-
tion was provided by comparing the independently refined
3.9 A˚ and 3.5 A˚ resolution IOMA–10-1074–BG505 structures.
Although the refined glycan B factors in the final models are
higher than in other published glycosylated Env structures,
our structures are not only the most extensively glycosylated,
but also represent the only complexes containing complex-
type N-glycans. Thus, the higher B factors are most likely to be
a reflection of the degree of glycosylation and the increased
heterogeneity owing to the presence of complex-type glycans.
4. Glycans in cryo-EM maps
We recently solved single-particle cryo-EM structures of the
Env trimer in order to visualize Env conformations that do not
readily form well ordered crystals. One structure, recon-
structed at 8.9 A˚ resolution, was of a complex between the
Env trimer, the host receptor CD4 and Fabs from two
different antibodies (Wang et al., 2016). A second structure at
6.2 A˚ resolution was an asymmetric complex of the Env trimer
bound to two, rather than three, apex-binding bNAb Fabs
(Wang et al., 2017). Density for ordered N-glycans at some
PNGSs was visible in both maps, and coordinates for ordered
N-linked glycans from our natively glycosylated Env trimer
structure (Gristick et al., 2016) were fitted separately as rigid
bodies at PNGSs at which EM density was apparent, and
geometric restraints for N-glycans were generated using
Privateer (Agirre et al., 2015). Fig. 5 compares N-linked glycan
densities in the 8.9 and 6.2 A˚ resolution maps.
5. Conclusions
Glycoprotein crystallography has generally been limited to
proteins with relatively low levels of N-linked glycans for
decades. Indeed, the unwritten (but discussed at conferences)
rule of thumb used to be that if your protein contained more
than one PNGS per 100 amino acids, you would need to either
remove selected PNGSs, use enzymatic deglycosylation,
produce a high-mannose form of the protein or perform all
three in order to obtain well ordered crystals. The HIV-1 Env
trimer was regarded as a difficult target for crystallization, as
depending on the viral strain it contains 30  3 PNGSs per
subunit. Thus, the first crystal structures of the HIV-1 Env
trimer were derived from proteins produced in high-mannose-
only forms that were usually further deglycosylated (Julien et
al., 2013; Pancera et al., 2014; Scharf et al., 2015; Garces et al.,
2015; Stewart-Jones et al., 2016). However, we recently showed
that it is possible to obtain crystal structures of fully and
natively glycosylated HIV-1 Env trimers despite using trimers
containing both complex-type and high-mannose glycans
(Gristick et al., 2016). In this case, crystallization was facili-
tated by adding antibody Fab fragments, which formed the
crystal lattice (Gristick et al., 2016), suggesting that other
heavily glycosylated proteins might be crystallized without
glycan trimming by adding nonglycosylated binding partners.
The heavy and heterogeneous glycosylation of the Env trimer
in our structures resulted in challenges for crystallographic
refinement that are described in more detail here than in our
original publication (Gristick et al., 2016).
Unlike structure determination by X-ray crystallography,
single-particle cryo-EM can be used for structures of natively
glycosylated proteins, no matter how heavily glycosylated.
Our cryo-EM structures of the natively glycosylated Env
trimer (Wang et al., 2016, 2017) were solved at low resolutions
(6.2 and 8.9 A˚), precluding the interpretation of glycan
conformations. However, densities for N-glycans were
apparent and we were able to use glycan coordinates from our
higher resolution crystal structures to interpret the lower
resolution density maps.
While these structures represent important steps towards
furthering our understanding of how antibodies interact with
complex-type glycans, advances in sample preparation, crystal
handling and/or data collection are required to further
increase the resolution (<3.0 A˚) of structures containing
complex-type glycans. Awealth of information about N-glycan
geometry and interactions with other proteins awaits the
solution of these technical problems.
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